mProX™ Human CD200 Stable Cell Line

Product Information

Target Family

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;WM266-4

Target Classification

CD Cell Lines

Target Research Area

Cancer Research

Related Diseases

Inflamed Seborrheic Keratosis; Hairy Cell Leukemia

Gene ID

Human:4345

UniProt ID

Human:P41217

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD200 has been studied in various applications. In the field of Alzheimer's disease (AD), CD200 has been explored in relation to the effects of angiotensin-converting enzyme inhibitors (ACEI) and statins therapies on AD-related neuropathology. The study found that treatment with ACEI and statins resulted in changes in the expression of CD200, among other proteins and genes, in both human patients and transgenic mice. CD200 was also found to be significantly affected by treatments in multiple myeloma (MM) patients, where its expression patterns were correlated with molecular genetic prognostic parameters. Additionally, CD200 has been investigated in the context of immune checkpoint disorders and Epstein-Barr virus (EBV) reactivation in immunodeficient patients with hematological malignancies. The study found that CD200 expression was altered in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and hairy cell leukemia (HCL), suggesting a potential interplay between immune checkpoint dysregulation and EBV reactivation. Furthermore, CD200 has been evaluated as a marker for the differential diagnosis of B-cell lymphoproliferative disorders (B-LPDs). The study found that CD200 expression could differentiate CLL from MCL, and HCL consistently expressed CD200. Lastly, CD200 has been studied in relation to neuroinflammation and amyloid-Œ≤ deposition in AD. Integrating transcriptomics and TSPO PET imaging, the study revealed that CD200 played a role in regulating neuroinflammation, AŒ≤ deposition, and cognitive dysfunction in AD patients. These findings highlight the potential applications of CD200 in various aspects of AD, MM, B-LPDs, and immunodeficiency-related hematological malignancies.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human CD200 Stable Cell Line (S01YF-1023-PY219). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Jordan Garcia (Verified Customer)

Can CD200 expression be altered in Parkinson's disease? Dec 25 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

CD200-CD200R1 signaling is altered in Parkinson's disease (PD), potentially affecting microglial function and representing a therapeutic target. Dec 25 2020

chat Casey Garcia (Verified Customer)

Does CD200 play a role in the tumor microenvironment? Oct 23 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

CD200 ectodomain shedding into the tumor microenvironment can lead to NK cell dysfunction and apoptosis, indicating its role as a potentially novel immune checkpoint. Oct 23 2020

Published Data

Fig.1 shRNA-mediated silencing of CD200 in human melanoma cells.

After being FACS-sorted for GFP expression, WM2664 human melanoma cells were examined for CD200 expression using immunofluorescence. When transduced with a CD200shRNA, WM2664 cells did not express CD200. When transduced with a nonspecific shRNA, WM2664 cells exhibited strong CD200 (red) staining. Original magnification, ×10.

Ref: Petermann, Kimberly B., et al. "CD200 is induced by ERK and is a potential therapeutic target in melanoma." The Journal of clinical investigation 117.12 (2007): 3922-3929.

Pubmed: 18008004

DOI: 10.1172/JCI32163

Research Highlights

Collu, Roberto. et al. "Angiotensin-converting enzyme inhibitors and statins therapies-induced changes in omics profiles in humans and transgenic tau mice." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023.
The relationship between hypertension and hyperlipidemia as risk factors for Alzheimer's disease (AD) and other related dementias has been extensively studied. Approved medications commonly used to treat these conditions have been linked to a decrease in the risk of developing AD, suggesting the possibility of repurposing them as therapeutic options. Further research is required to fully investigate the potential benefits of these medications in the prevention and treatment of AD.
Collu, Roberto. et al. "Angiotensin-converting enzyme inhibitors and statins therapies-induced changes in omics profiles in humans and transgenic tau mice." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023.
Pubmed: 37865996 DOI: 10.1016/j.biopha.2023.115756

Wang, Ping. et al. "Correlation between Expression Patterns of CD117/CD200 in Plasma Cells and Molecular Genetic Prognostic Parameters in Multiple Myeloma."Zhongguo shi yan xue ye xue za zhi 31.5 (2023): 1415-1420.
This study aims to examine the relationship between the levels of CD117 and CD200 in plasma cells and genetic abnormalities in individuals diagnosed with multiple myeloma (MM). The expression of these markers will be measured and compared in a sample of MM patients to determine if there is a correlation between their levels and the presence of molecular genetic abnormalities. The findings of this investigation will contribute to a better understanding of the pathogenesis of MM and potentially aid in the development of targeted treatments.
Wang, Ping. et al. "Correlation between Expression Patterns of CD117/CD200 in Plasma Cells and Molecular Genetic Prognostic Parameters in Multiple Myeloma."Zhongguo shi yan xue ye xue za zhi 31.5 (2023): 1415-1420.
Pubmed: 37846693 DOI: 10.19746/j.cnki.issn.1009-2137.2023.05.025